Trade Summary

6 days ago, Robin Howard W, serving as Pres, CEO at Nektar Therapeutics (NKTR), sold 444 shares at $65.51 per share, for a total transaction value of $29,086.00. Following this transaction, Robin Howard W now holds 75,073 shares of NKTR.

This sale represents a 1.00% decrease in Robin Howard W's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Tuesday, May 19, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, May 21, 2026 at 6:26 PM ET, 2 days after the trade was made.

Nektar Therapeutics operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.